Re: AGM - Jan 7, 2016 - Details
in response to
by
posted on
Jan 08, 2016 11:24AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
masila, thanks very much for your excellent detailed report! That was quite a bit of work and it's greatly appreciated!
It was interesting to note that...
"Current Zenith shareholders will own shares of both ZCC and ZEL."
I still don't have much of a feel for how current share ownership would translate into ownership in an IPO or asset sale. I'm still thinking substantial dilution, but it's hard to tell. BUT, overall, the future looks promising.